Castlight Health (CSLT) executive Bondurant returned to the company 355,661 shares

Insider transactions reported

William Bondurant (executive at Castlight Health Inc., CSLT) reported that they returned to the company 355,661 shares between Jan 12, 2022 and Feb 17, 2022. After these transactions the filing shows 0 shares held directly.

Reporting person

Bondurant William

Options and other derivatives

Holdings before and after

• Class B Common Stock: 355,661 to 0 direct
• Employee Stock Option (right to buy): 1,750 to 0 direct
• Employee Stock Option (right to buy: 5,757 to 0 direct

Footnotes from the filing

1. 1. Pursuant to the Agreement and Plan of Merger (the Merger Agreement ), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ( Vera Health ), and Carbon Merger Sub, Inc. (the Merger Sub ), the Merger Sub merged with and into the Issuer (the Merger ), with the Issuer surviving the Merger (the Surviving Corporation ), as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the Effective Time ). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash (the Merger Consideration ) at the Effective Time.
2. 2. Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration.
3. 3. 1/3 of the RSUs vested on February 16, 2022 and the remainder will vest quarterly over two years in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
4. 4. 1/16th of the RSUs vested on November 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
5. 5. Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the RSU Consideration ). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date.
6. 6. 1/16th of the RSUs vested on May 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
7. 7. 1/16th of the RSUs vested on February 16, 2020, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
8. 10. The option is fully vested and exercisable.
9. 11. Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a Permitted Transferee , as defined in the Issuer's Restated Certificate of Incorporation in effect immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date.
10. 12. Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time.
11. 13. Pursuant to the Merger Agreement, the option was cancelled and converted at or immediately prior to the Effective Time into a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option.
12. 14. The option exercise price is equal to or exceeds the Merger Consideration and therefore the option was automatically cancelled without consideration immediately prior to the Effective Time.
13. 15. The option vested as to 1/12th of the total number of shares on May 16, 2019, and thereafter vests in equal quarterly installments, subject to the continuing service of the Reporting Person on each vesting date.
14. 16. The option vested as to 1/16th of the total number of shares on February 16, 2020, and thereafter vests 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
15. 17. Pursuant to the Merger Agreement, to the extent vested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option. To the extent unvested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash replacement amount equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price (the Option Consideration ). [Continued in fn (18)]
16. 18. [Continuation of fn (17)] The payment of the Option Consideration will be subject to vesting in accordance with the vesting schedule applicable to the unvested portion of the option immediately prior to the Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date.

Transaction codes in this filing

Sale back to the company:

Code D marks a disposition back to the company under an exempt plan, as opposed to a sale in the market.

FAQ